Delivery Order SPE2DB25D3202-SPE2DB25FSZRT

Award Date 2/25/25
Potential Completion Date 2/26/25
Potential Value $3.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA), a defense agency. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $3,544.81 and is a firm fixed-price delivery order with a completion date of January 13, 2025. The contract is not designated as a set-aside award. Amerisourcebergen Drug Corp holds a significant...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML medical products to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price of $5,111.46 and an ultimate completion date of December 16, 2024. It is a delivery order contract and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The $5,773.01 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of October 11, 2024 and was awarded on October 10, 2024. This is a delivery order contract without any set-aside requirements, indicating open competition. AmerisourceBergen holds...
This federal contract award is for the delivery of GARDASIL 9 vaccine syringes (0.5 ml) to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on February 28, 2023 for a ceiling value of $109,758.19. The contract is a delivery order with a firm fixed price pricing type and has an ultimate completion date of March 1, 2023. This contract is not designated as a...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The $10,009.41 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 7, 2025, with a final completion date of February 10, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA) Troop Support Medical. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price of $3,294.90 and an ultimate completion date of December 27, 2024. This award is not designated as a set-aside contract. The contract is part of a larger Indefinite Delivery...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies. The contract, valued at $15,773.30, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $25,353.88 firm fixed-price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 17, 2025, with a completion date of January 21, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a...
The federal contract award is for the delivery of GARDASIL 9 syringes (0.5ML) to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $28,787.47, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, through a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. The contract has a completion date of September 10, 2024 and is a Firm Fixed Price arrangement. There is no set-aside designation for this...
This federal contract award is for the delivery of GARDASIL 9 syringes, 0.5 ml each, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $6,107.19 and an ultimate completion date of May 3, 2023. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA...
  • SPE2DB25D3202
    Indefinite Delivery Contract
  • SPE2DB25D3202-SPE2DB25FSZRT
    Delivery Order

This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on February 25, 2025 with a completion date of February 26, 2025. The contract has a firm fixed price of $3,267.98 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/27/25, 9:46 AM